Home › High Blood Pressure › NCT04546126

Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria (Groups 2 \& 3):

* Participants without any known adrenal pathology as normal controls for undergoing endocrine manipulation

Exclusion Criteria (Groups 2 \& 3):

* Pregnancy
* Unable to do imaging
* Body weight greater than 400 lbs (181 Kg)
* Prisoners are not eligible
* Subjects unable to provide own consent are not eligible
* Current use of steroids, Oral contraceptives (OCP), spironolactone, estrogen, androgen, progesterone, Angiotensin-converting enzyme (ACE inhibitors)/ Angiotensin II receptor blockers (ARBs), or supplements that are hormone analogues.
* Known adrenal pathology

Inclusion Criteria (Group 4):

* Abnormal adrenal cortical hormone secretion

Exclusion Criteria (Group 4):

* Pregnant

About the study

This study will evaluate the feasibility of using a sub-therapeutic dose of a fluorine-18 analogue of NP-59 (\[18F\]FNP-59) to image the adrenal gland. Some participants are healthy normal subjects but have undergone interventions to manipulate hormones while other participants have known adrenal pathology.

What is being tested

• Dexamethasone (Group 2) (drug)
• Cosyntropin (Group 3) (drug)
• PET/CT Scan with FNP-59 (combination product)

Sponsor: Benjamin Viglianti · Participants: 24 · Started: Nov 1, 2021

Contact the study team

• Jim Pool · Phone: 734-615-7391

Official record on ClinicalTrials.gov — NCT04546126

Locations in the U.S.

Conditions

• High Blood Pressure

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.